Folate Deficiency

Introduction and Pathophysiology

• Folate is a water-soluble vitamin essential for DNA replication, cellular proliferation, and single-carbon transfer reactions.
• Humans cannot synthesize folate and rely on dietary sources (green vegetables, fruits, animal organs).
• Dietary folate occurs in a polyglutamate form, which is hydrolyzed in the intestinal brush border, absorbed primarily in the duodenum and upper small intestine, and transported to the liver where it is converted into 5-methyltetrahydrofolate, the principal circulating form.
• Because the body has limited stores of folate, a deficiency can develop rapidly (within 2 to 3 months) if placed on a folate-free diet.
• The peak incidence for megaloblastic anemia due to folate deficiency in childhood occurs between 4 and 7 months of age.

Etiology

Inadequate Nutritional Intake

• Malnutrition is the most common cause of folate deficiency in older children.
• Exclusive feeding with goat's milk is a classic cause of deficiency, as it is profoundly folate-deficient (containing only 6 mg/L).
• Poor food preparation methods contribute to deficiency, as folates are heat-labile and water-soluble; boiling or excessive heating destroys the vitamin.

Increased Requirements

• Accelerated growth during prematurity, infancy, and pregnancy significantly increases physiologic folate demands.
• Chronic hemolytic anemias characterized by rapid red cell turnover (e.g., sickle cell disease, thalassemia, hereditary spherocytosis, pyruvate kinase deficiency) substantially increase requirements.
• Hypermetabolic states such as hyperthyroidism, extensive exfoliative skin diseases (psoriasis, dermatitis herpetiformis), and hemodialysis also predispose to deficiency.

Defective Absorption

• Generalized malabsorption syndromes, including celiac disease, tropical sprue, and inflammatory bowel disease, impair folate uptake.
• Chronic diarrheal states disrupt the enterohepatic circulation of folate, leading to accelerated loss via rapid intestinal transit.
• Surgical alterations, such as jejunal resection or the presence of enteroenteric fistulas, reduce absorptive capacity.

Drug-Induced Abnormalities

• Dihydrofolate reductase (DHFR) inhibitors, such as methotrexate, pyrimethamine, and trimethoprim, directly block the conversion of folate to its active tetrahydrofolate form.
• Anticonvulsant medications (e.g., phenytoin, phenobarbital, valproic acid) can impair intestinal folic acid absorption.
• Other implicated medications include sulfasalazine and oral contraceptives.

Inborn Errors of Folate Metabolism and Transport

• Hereditary Folate Malabsorption (HFM): A rare autosomal recessive disorder caused by loss-of-function variants in the SLC46A1 gene (encoding the protein-coupled folate transporter). It impairs folate transport in both the intestines and the choroid plexus of the brain.
• Other rare metabolic defects include methylenetetrahydrofolate reductase (MTHFR) deficiency, glutamate formiminotransferase deficiency, and dihydrofolate reductase deficiency.

Clinical Manifestations

• Patients typically present with an insidious onset of anemia symptoms, including progressive pallor, lethargy, fatigue, anorexia, and poor weight gain.
• Gastrointestinal mucosal changes are prominent, manifesting as a sore, red, and smooth tongue (glossitis), stomatitis, and chronic diarrhea.
• Dermatologic signs can include characteristic hyperpigmentation of the skin, particularly over the knuckles and terminal phalanges.
• In severe, advanced cases, thrombocytopenia may cause hemorrhagic manifestations such as petechiae and purpura.
• Maternal folate deficiency during pregnancy is strongly linked to neural tube defects, fetal growth restriction, and prematurity.
• Neurologic symptoms (seizures, developmental delay, hypotonia, and intellectual disability) are not typical of simple dietary folate deficiency but are classically seen in Hereditary Folate Malabsorption due to deficient folate transport into the central nervous system.

Laboratory Findings

Hematologic Profile

• Red Blood Cells: Macrocytic anemia is the hallmark, with the mean corpuscular volume (MCV) significantly elevated (typically 100–140 fL) alongside an increased red cell distribution width (RDW).
• Reticulocyte Count: Inappropriately low (reticulocytopenia) for the degree of anemia.
• White Blood Cells and Platelets: Leukopenia (1500–4000/mm³) and thrombocytopenia (50,000–180,000/mm³) may develop in advanced deficiency, closely mimicking bone marrow failure or leukemia.
• Peripheral Blood Smear: Reveals macro-ovalocytes, prominent anisopoikilocytosis, teardrop cells, Cabot rings, Howell-Jolly bodies, and punctate basophilia. Nucleated red blood cells with megaloblastic morphology may be visible.
• Neutrophil Morphology: Neutrophils are characteristically large and hypersegmented, defined as having a nucleus with more than 5 lobes in greater than 5% of the neutrophils.

Bone Marrow Examination

• The marrow is markedly hypercellular due to erythroid hyperplasia driven by increased erythropoietin levels.
• Classic megaloblastic changes are present, characterized by nuclear-cytoplasmic asynchrony where the nucleus appears developmentally delayed, exhibiting an open, stippled, or lacy chromatin pattern.
• Giant metamyelocytes and abnormally large neutrophil bands with cytoplasmic vacuolation are commonly seen.

Biochemical Markers

• Markers of ineffective erythropoiesis are elevated, including markedly increased lactate dehydrogenase (LDH), increased indirect bilirubin, elevated serum iron, and decreased serum haptoglobin.
• Folate Levels: Serum folate levels less than 3 ng/mL suggest deficiency. However, the red blood cell (RBC) folate level (normal: 150–600 ng/mL) is a much more sensitive and reliable indicator of chronic tissue folate stores, with values less than 160 ng/mL indicating true deficiency.
• Vitamin B12: Serum cobalamin levels are normal.
• Metabolites: Serum homocysteine levels are elevated in folate deficiency. Crucially, serum methylmalonic acid (MMA) levels remain strictly normal. A normal MMA level is the definitive laboratory parameter used to distinguish isolated folate deficiency from Vitamin B12 deficiency (where both MMA and homocysteine are elevated).

Management and Treatment

Initial Considerations

• Vitamin B12 deficiency must be rigorously excluded before initiating folic acid therapy.
• Administering pharmacologic doses of folic acid to a patient with undiagnosed Vitamin B12 deficiency may rapidly correct the hematologic abnormalities (anemia) but will fail to halt, and may actively accelerate or precipitate, irreversible subacute combined degeneration of the spinal cord.

Medical Therapy

• Standard Replacement: The treatment of choice for simple nutritional deficiency or malabsorption is oral folic acid administered at a dose of 0.5 to 1.0 mg/day (or 1 to 5 mg/day depending on severity and guidelines).
• This dose is sufficient even in the presence of generalized malabsorption syndromes and is typically continued for 3 to 4 weeks, or until a definitive hematologic response is achieved and a completely new population of red cells is produced.
• Maintenance: Following initial correction, maintenance therapy with a daily multivitamin containing 0.2 mg of folate is usually adequate.
• Lifelong Supplementation: Patients with chronic hemolytic anemias (e.g., sickle cell disease, hereditary spherocytosis) or irreversible chronic malabsorption require continuous, lifelong supplementation, typically at 1 mg/day.
• Drug-Induced Deficiency: Folic acid deficiency triggered by DHFR inhibitors (like methotrexate or pyrimethamine) requires specific treatment with folinic acid (5-formyltetrahydrofolate or leucovorin), which bypasses the enzymatic blockade.
• Hereditary Folate Malabsorption: Requires lifelong parenteral (intramuscular) folate or massive oral doses of folinic acid to achieve adequate central nervous system penetration and prevent irreversible neurologic sequelae.

Response to Therapy

• The clinical and hematologic response to folate therapy is extremely rapid and robust.
• Clinical symptoms (alertness, appetite) often improve within a few days.
• The bone marrow begins reverting from megaloblastic to normoblastic morphology within 1 to 2 days.
• Peripheral reticulocytosis begins on days 2 to 4 and reaches a peak between days 4 and 7.
• Hemoglobin levels, leukocyte counts, and platelet counts completely normalize within 2 to 6 weeks.
• Blood transfusions are generally avoided and reserved strictly for patients exhibiting severe, life-threatening cardiovascular compromise or shock secondary to profound anemia.